SPARC2023-04-012023-06-30 SPARC2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SPARC2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member SPARC2023-04-012023-06-30in-bse-fin:OneOperatingExpenses03Member SPARC2023-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532872 SPARC NA Sun Pharma Advanced Research Company Limited Equity 2023-04-01 2024-03-31 2023-08-07 2023-07-29 INR Lakhs First quarter 11:30:00 14:55:00 2023-08-07 2023-08-07 Not applicable Single segment Pharmaceutical Research and Development 2023-04-01 2023-06-30 Unaudited Standalone 239500000.00 101900000.00 341400000.00 51700000.00 0.00 0.00 311200000.00 2600000.00 31000000.00 898400000.00 1294900000.00 -953500000.00 0.00 -953500000.00 0.00 0.00 0.00 0.00 -953500000.00 0.00 0.00 0.00 0.00 -953500000.00 3400000.00 -950100000.00 0.00 0.00 324500000.00 1 -2.94 -2.94 0.00 0.00 -2.94 -2.94 1. The above unaudited financial results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on August 7, 2023 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company. 2. During the previous quarter, the Company had paused the development of SC0-120 program due to changing clinical landscape. Pursuant to this, the Company had made provision for committed costs for this program estimated at, 2,700 lakhs. 3. The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'. 4. The figures of the previous quarter is the balancing figures between audited figures in respect of the full financial year up to March 31, 2023 and the unaudited published year-to-date figures up to December 31, 2022, being the date of the end of the third quarter of the previous financial years which was subjected to limited review. 5 Previous period figures have been regrouped/ rearranged, wherever necessary. Clinical trial expenses / products development expense 369800000.00 Other expenses 115100000.00 Professional charges 413500000.00 -3400000.00 0.00